Reported Saturday, Incyte Unveils Results For CDK2 Inhibitor INCB123667 In Advanced Solid Tumors, Ovarian Cancer Among Highlighted
Reported Saturday, Incyte Unveils Results For CDK2 Inhibitor INCB123667 In Advanced Solid Tumors, Ovarian Cancer Among Highlighted
根據週六報道，因塞特在先進實體腫瘤、卵巢癌等方面公佈了CDK2抑制劑INCB123667的結果。
- New antitumor response data from a range of doses and regimens unveiled today at Incyte investor event
- These results build upon safety and tolerability data presented earlier today during a mini-oral presentation at the European Society of Medical Oncology (ESMO) Congress 2024
- Findings support the initiation of a pivotal trial in ovarian cancer, expected to begin in 2025; additional plans to evaluate INCB123667 in combination with other treatments are underway
- 因塞特投資者活動今天公佈了來自不同劑量和方案的新抗腫瘤反應數據。
- 這些結果是在2024年歐洲醫學腫瘤學會（ESMO）大會舉行的迷你口頭報告中提出的安全性和耐受性數據的基礎上建立的。
- 研究結果支持在2025年開展卵巢癌關鍵試驗的啓動，並且計劃通過評估與其他治療方法聯合使用INCB123667來推進額外的計劃。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間